

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECT
Int

INTERNATIONAL APPLICATION PUBLISHED



(51) International Patent Classification 6 :

A61K 9/107, 47/10

A1

(11) International Publication Number:

WO 96/03113

(43) International Publication Date:

8 February 1996 (08.02.96)

(21) International Application Number: PCT/US95/08227

(22) International Filing Date: 10 July 1995 (10.07.95)

(30) Priority Data:

08/278,766

22 July 1994 (22.07.94)

US

(60) Parent Application or Grant

(63) Related by Continuation

US

08/278,766 (CON)

Filed on

22 July 1994 (22.07.94)

(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOKHALE, Rajeev, D. [IN/US]; 114 Brandywine Court, Vernon Hills, IL 60061 (US). GRIFFIN, Martin, J. [US/US]; 4821 Crain, Skokie, IL 60077 (US). TRUELOVE, James, E. [US/US]; 1006 Regency Lane, Libertyville, IL 60048 (US). STOLZENBACH, James, C. [US/US]; 278 Stanton Drive, Buffalo Grove, IL 60089 (US). KARIM, Aziz [US/US]; 225 Greenleaf,

Skokie, IL 60077 (US). ROY, Ajit, K. [BD/US]; 1124 Londmeadow Drive, Glenview, IL 60025 (US).


(74) Agents: UNGEMACH, Frank, S. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: SELF-EMULSIFYING DRUG DELIVERY SYSTEM



(57) Abstract

Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and a solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

SELF-EMULSIFYING DRUG DELIVERY SYSTEMBACKGROUND OF THE INVENTION

5 The primary targets for any dosage formulation is to deliver the necessary concentration of an active drug to the site of action to elicit the desired therapeutic response and to maintain an effective concentration of the drug for a sufficient period to achieve efficacious
10 treatment. Oral administration is generally preferred but is frequently dependent upon the bioavailability of the active form of the drug, i.e., the rate and extent that the active form of the drug appears from the dosage form in the systemic circulation. Bioavailability is
15 affected by the drug's physical chemical properties, such as pKa, water solubility, oil solubility and stability, as well as its absorption, distribution, metabolism and excretion. It is well known that water insoluble drugs are not generally available for absorption through
20 intestinal lumen and oil insoluble drugs are generally unable to pass across intestine cell membranes into systemic circulation (S.H. Yalkowsky, "DRUGS OF THE PHARMACEUTICAL SCIENCES: TECHNIQUES OF SOLUBILIZATION OF DRUGS," Marcel Dekker, Inc., Vol. 12, 1981). Proper
25 formulation can improve the bioavailability.

 Oral dosage formulations for water soluble or oil soluble drugs are well known. Oral dosage formulations for oil soluble drugs typically require that the oil form an aqueous emulsion. The emulsion may form in the
30 stomach, for example an oil solution in soft gelatin capsules, or be prepared prior to consumption, for example mixing emulsifiable concentrates with an aqueous solution. In both cases, the oil should readily emulsify when released in an aqueous environment. Oils which rapidly
35 emulsify without the use of sophisticated emulsification equipment, such as with gentle shaking or mixing, are known as self-emulsifiable oils. Dosage formulation that

utilize such self-emulsifiable oils as known as self-emulsifying drug delivery systems or SEDDS (Charman et al., Pharm. Res. 9:87-93, 1992). Such self-emulsifiable oils are well known and include hydrocarbon oils combined with a surfactant (Iranloye and Pilpel, J. Pharm. Sci. 73:1267-1270, 1984) and vegetable oils combined with a non-ionic surfactant (Wakerly et al., J. Pharm. Pharmacol. 39:suppl. 6p, 1987). More recently, the use of polyglycolized glycerides with varying fatty acids and polyethylene glycols chain lengths were used in SEDDS formulations of hydrophobic drugs with adequate oil solubility (Shah et al., Int. J. Pharm. 106:15-23, 1994).

A problem arises when the drug is substantially insoluble in both water and oil. In such cases, the drug is typically poorly bioavailable at best and traditional oral dosage formulations tend not to substantially improve its bioavailability.

BRIEF DESCRIPTION OF THE INVENTION

The present invention is directed to oral dosing formulations of pharmaceuticals which are substantially insoluble in both water and oil. The formulations comprise a pharmaceutical which is substantially water and oil insoluble, an emulsifier, an oil and a solubilizer. Alternatively, the formulation comprises a pharmaceutical which is substantially water and oil insoluble and an aqueous solution of solubilizer.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the plasma concentration-time curves of a pharmaceutical with elixir fasting and SEDDS fasting. Figure 2 shows the plasma concentration-time curves of a pharmaceutical with elixir fasting and SEDDS fed. Figure 3 shows the plasma concentration-time curve of a pharmaceutical with SEDDS fed along with the IC_{50} and IC_{90} pharmaceutical plasma levels.

Figure 4 shows the simulated steady state plasma concentration-time curves of a pharmaceutical with elixir fasting and SEDDS fed.


5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a means for orally delivering the necessary concentration of an active form of a pharmaceutical which is substantially insoluble in both water and oil to the systemic circulation of an animal or human being to elicit a desired therapeutic response. Pharmaceuticals, which would otherwise be good candidates for use in treatments, are frequently dropped or rejected due to their substantial insolubility in both water and oil. This insolubility problem typically results in low, if any, bioavailability of the pharmaceutical.

As a class, HIV protease inhibitors tend to have low oral bioavailability and short plasma half-lives. Thus it is difficult to maintain adequate therapeutic blood levels of the drug for a prolonged time period. Surprisingly, by solubilizing the water and oil insoluble pharmaceutical with a solubilizer in the dosage formulation of the present invention, the pharmaceutical's bioavailability substantially increases. For example, the compound N¹-[3-[N²-[[(1,1-dimethylethyl)amino]carbonyl]-N²-(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N³-(2-quinolinylcarbonyl)amino]butanediarnide which has the formula

30



is an effective HIV protease inhibitor (see US patent application Serial No. 08/152,934, filed November 15, 1993, incorporated herein by reference in its entirety).

5 Because of its low solubility in both water (about 0.01 mg/mL) and oil (less than 1 mg/mL), its bioavailability was also very low when measured in animals. By utilizing a solubilizer in the dosage formulation, the bioavailability increased about 25-50 fold thereby making
10 the compound a potentially effective pharmaceutical for the treatment of HIV infections.

The present invention can also be used with other pharmaceuticals which are not only substantially insoluble in both water and oil, but which are substantially
15 insoluble in water or oil or soluble in water or oil. Such pharmaceuticals include, but are not limited to, Ro 31-8959 (Roberts, N.A. et al. Science 1990, 248, 358-361 and Drugs of the Future 1991, 16(3), 210-212); cyclosporin; FK506 (immunomodulator); [1S-[1R*(R*),2S*]]-
20 2-(acetylamino)-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methyl-butyl)amino]-2-hydroxy-1-(4-fluorophenylmethyl)propyl]-3,3-dimethyl-butaneamide; [1S-[1R*(2S*,3R*),2S*]]-N1-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
25 hydroxy-1-(phenylmethyl)propyl]-2,3-dimethyl-butanediamide; [1S-[1R*(R*),2S*]]-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(2-hydroxy-1-(phenylmethyl)propyl)-2-methyl-3-(2-phenylethylsulfonyl)-
30 propanamide and its diastereomer; [1S-[1R*(S*),2S*]]-3-(4-methoxybenzyl-oxycarbonyl)-N-[3-[[[(1,1-dimethylethyl)amine]carbonyl]3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-propanamide; [1S-[1R*(R*),2S*]]-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
35 hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-propanamide and its diastereomer; [2R-hydroxy-3-[N-(-4-hydroxyphenylsulfonyl)-N-(2-

- methylpropyl) amino]-1S-(phenylmethyl)propyl-carbamic acid 3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester; [2R-hydroxy-3-[(4-methoxyphenylsulfonyl) (2-methylpropyl) amino]-1S-(phenylmethyl)propyl-carbamic acid 3(S)-1,1-
- 5 dioxotetrahydrothiophen-3-yl-ester; N-[2R-hydroxy-3-[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2,6-dimethylbenzamide; N-[2R-hydroxy-3-[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2-
- 10 methylbenzamide; N-[2R-hydroxy-3-[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2,5-dimethylbenzamide; [1S-[1R*(S*),2S*]]-3-[[2-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl) amino]-1-
- 15 (phenylmethyl)propyl] amino]-2-methyl-3-oxopropyl]-carbamic acid (4-methoxyphenyl)methyl ester; N¹-[2R-hydroxy-3-[(3-methylbutyl) (phenyl-sulfonyl) amino]N⁴-methyl-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide; [1S-
- 20 [1R*(S*),2S*]]-n4-[2-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl) amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-butanediamide; [1S-[1R*(R*),2S*]]-N-[2-hydroxy-3-[(3-methylbutyl) [(4-aminophenylsulfonyl) amino]-1-(phenylmethyl)propyl]-2-
- 25 methyl-3-(methylsulfonyl)-propanamide; and 8-chlorodibenz[b,f][1,4]oxazapine-10-(11H)-carboxylic acid, 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide.

The present invention is particularly beneficial for pharmaceuticals with a dose to solubility ratio in excess

30 of about 1000 and even more beneficial for pharmaceuticals with a dose to solubility ratio in excess of about 10,000. For example, dose to solubility ratio of the compound N¹-[3-[N²-[(1,1-dimethylethyl) amino] carbonyl]-N²-(2-methylpropyl) amino]-2(R)-hydroxy-1(S)-(phenylmethyl)

35 propyl]-2(S)-[N³-(2-quinolinyl carbonyl) amino]butanediamide was determined to be in excess of about 75,000.

The present invention is an oral pharmaceutical composition comprising a) a pharmaceutical which is substantially water and oil insoluble; b) an edible emulsifier; c) an edible oil; and d) an edible solubilizer. The pharmaceutical may be at a concentration within the range of about 0.1 to about 17% (w/w); preferably, at a concentration within the range of about 2 to about 10% (w/w); and more preferably, at a concentration ~~within the range of about 5 to about 10% (w/w)~~. The emulsifier may be at a concentration within the range of about 10 to about 55% (w/w); preferably at a concentration within the range of about 10 to about 45% (w/w); and more preferably, at a concentration within the range of about 30 to about 45% (w/w). The oil may be at a concentration within the range of about 10 to about 50% (w/w); preferably, at a concentration within the range of about 10 to about 45% (w/w); and more preferably, at a concentration ~~within the range of about 25 to about 45% (w/w)~~. The solubilizer may be at a concentration within the range of about 2 to about 50% (w/w); preferably, at a concentration within the range of about 5 to about 40% (w/w); and more preferably, at a concentration within the range of about 10 to about 35% (w/w).

Alternatively, the present invention is an oral pharmaceutical composition comprising a) a pharmaceutical which is substantially water and oil insoluble; b) an edible solubilizer; and c) water. The pharmaceutical may be at a concentration within the range of about 0.1 to about 17% (w/w), and preferably, at a concentration within the range of about 2 to about 10% (w/w). The solubilizer may be at a concentration in the water within the range of about 40 to about 90% (w/w); preferably, at a concentration within the range of about 50 to about 80% (w/w); and more preferably, at a concentration within the range of about 60 to about 80% (w/w). The solubilizer concentration will frequently depend on the solubility properties of the pharmaceutical and the total volume of the dose.

An "edible emulsifier" is an emulsifier which may be consumed by an animal or human being without substantial side effects or substantial toxic reaction. Emulsifiers which are suitable for use in this invention include

5 polyoxyethylene glycerol esters of fatty acids, such as Tagat TO, Tagat L, Tagat I, tagat I2 and Tagat O (commercially available from Goldschmidt Chemical Co., Essen, Germany); ethylene glycol esters, such as glycol stearate and distearate; propylene glycol esters, such as

10 propylene glycol myristate; glyceryl esters of fatty acids, such as glyceryl stearates and monostearates; sorbitan esters, such as spans and tweens; polyglyceryl esters, such as polyglyceryl 4-oleate; fatty alcohol ethoxylates, such as Brij type emulsifiers; ethoxylated

15 propoxylated block copolymers, such as poloxamers; polyethylene glycol esters of fatty acids, such as Labrafil 2125 Cs, Labrafil M 1944 CS and Labrasol; cremophores, such as cremophore E and Cremophore RH 40P; glycerol monocaprylate/caprate, such as Campmul CM 10; and

20 the like, Tagat TO is preferred.

An "edible oil" is an oil which may be consumed by an animal or human being without substantial side effects or substantial toxic reaction. Most edible oils are suitable for use in this invention, including Neobee oil

25 (commercially available from Stephan Co., IL), Myglyol derivatives (fractionated coconut oil), soy oil, almond oil, olive oil, peanut oil, other fatty acid esters of glycerols having about 14 to about 18 carbon atoms, medium chain triglycerides having about 8 to about 10 carbon

30 atoms, and the like. Neobee oil is preferred.

An "edible solubilizer" is a material which can dissolve a pharmaceutical that is substantially insoluble in water and oil and may be consumed by an animal or human being without substantial side effects or substantial

35 toxic reaction. Solubilizers which are suitable for use in this invention include ethanol, tert-butanol, sweet peppermint flavor, orange oil flavor, cherry flavor, raspberry flavor, lemon oil flavor, oleic acid, linoleic

acid, propylene glycol, butyric acid, propionic acid, lauryl alcohol, limonene, myristyl alcohol, polyethylene glycol and the like. Ethanol is preferred.

"Substantially water insoluble" means that the
5 measurable solubility in water (pH 7) is preferably less than one part per hundred, more preferably less than one part per thousand and more preferably less than one part per ten thousand.

"Substantially oil insoluble" means that the
10 measurable solubility in oil is preferably less than one part per hundred, more preferably less than one part per thousand and more preferably less than one part per ten thousand.

Typically the formulation of the present invention
15 is prepared by forming an "emulsifiable concentrate" comprising the pharmaceutical, solubilizer, emulsifier and oil in the final concentration ranges disclosed above.

The emulsifiable concentrate is preferably prepared by first dissolving the pharmaceutical in the solubilizer.
20 The pharmaceutical is preferably fully dissolved in the solubilizer, which may require vigorous mixing, stirring or heating. This solution is combined with the emulsifier to form a uniform solution. This mixture is then combined with the oil to form the emulsifiable concentrate.

25 The emulsifiable concentrate may be used directly, for example, as an elixir or in soft gelatin capsules, or may be combined with an aqueous solution prior to distribution or use. Because a preferred emulsifiable concentrate spontaneously forms emulsions in aqueous
30 solutions, it may be combined with the aqueous solution just prior to use which can minimize the effect of any long term emulsion instability. It may be necessary in some formulations to combine the emulsifiable concentrate with the aqueous solution just prior to use to avoid
35 gelling of the mixture. For example, the composition of Tagat TO, Neobee Oil, ethanol and an aqueous solution has been observed to form a gel above five degree Celsius. The aqueous solution may be water (such as buffered

water), beverages (such as soft drinks, milk and the like, juices (such as orange juice, grape juice, apple juice, and the like) and the like. Preferably, the aqueous solution has a pH within the range of about 3 to about 8.5 and more preferably, within the range of about 5 to about 7.5. The preferred ration of emulsifiable concentrate to aqueous solution, i.e., oil:water ratio, is within the range of about 1:50 to about 1:200.

The particle size of the emulsion particles may be critical to the effectiveness of the present invention. The smaller the emulsion particles, the larger the total surface area and the greater the likelihood of absorption into the systemic circulation. The particle size distribution can be readily determined from dynamic light scattering techniques well known in the art. Preferably the mean emulsion particle size is within the range from about 20nm to about 25nm in diameter and more preferably, about 22nm in diameter.

With regards to the compound N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl) propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide, a preferred formulation under the present invention is about 5% (w/w) pharmaceutical, about 35% (w/w) Tagat TO, about 25% (w/w) Neobee Oil and about 35% (w/w) ethanol.

While the pharmaceutical of the present invention may be administered as the sole active pharmaceutical agents, the pharmaceutical may also be used in combination with other pharmaceuticals which are effective for the same treatment. These additional pharmaceuticals may be added to the formulation of present invention any may be water soluble, oil soluble, or substantially water or oil insoluble. For example, N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide may be administered as the sole active pharmaceutical agent, it may also be used in combination with other antiviral agents which are

effective against retroviruses such as HIV. Such compounds include, but are not limited to, other HIV protease inhibitors, various nucleoside analogs, nonnucleoside reverse transcriptase inhibitors, tat antagonists and glycosidase inhibitors (US patent application Serial No. 08/253,638, filed June 3, 1994, which is incorporated by reference herein in its entirety). Such other antiviral agents may also be added to the formulation of the present invention.

10 Examples of HIV protease inhibitors include, but not limited to, Ro 31-8959 (Roberts, N.A. et al. Science 1990, 248, 358-361 and Drugs of the Future 1991, 16(3), 210-212), KNI-272, (Kagayama, S., et al. Antimicrobial Agents and Chemotherapy 1993, 810-817), the cyclic urea series
15 (Lam, P., et al., "De Novo Design and Discovery of Potent, Nonpeptidal HIV-1 Protease Inhibitors," paper 96 at the 205th American Chemical Society National Meeting, Medicinal Chemistry Division, Denver, CO, March 28-April 2, 1993), L-735,524 (Dorsey, B.D., et al., "L-735,524:
20 The Rational Design of a Potent and Orally Bioavailable HIV Protease Inhibitor," paper 6 at the 206th American Chemical Society National Meeting, Medicinal Chemistry Division, Chicago, IL, August 22-27, 1993) and analogs thereof. Examples of glycosidase inhibitors include, but
25 are not limited to, castanospermine, castanospermine 6-butyryl ester, N-butyl-1-deoxynojirimycin, N-butyl-1-deoxynojirimycin per-butyryl ester and analogs thereof.

Other pharmacologically active or inactive compounds, excipients or additives may be added to the
30 formulation to enhance the efficacy of the pharmaceutical, to reduce the side effects and/or toxic effects of the pharmaceutical, to prolong the duration of the active form of the pharmaceutical in the systemic circulation and the like. Additional ingredients may also be added to the
35 formulation which enhance the stability of the pharmaceutical or formulation, such as anti-oxidants (BHA, BHT, vitamin E, ascorbyl palmitate and the like). Still other ingredients may be added to the formulation, such as

colorings, flavorings (sweet peppermint flavor, orange oil flavor, cherry flavor, raspberry flavor, lemon oil flavor and the like), sweeteners (aspartame, saccharin, glucose, sucrose, dextrose and the like) and the like to enhance
5 the receptivity and compliance by patients or other users of the formulations.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description,
10 utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

15 Example 1

Preparation of [1S-[1R*(R*), 2S*]]-N¹[3-[[[1,1-dimethylethyl)aminolcarbonl (2-methylpropyl)aminol -2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)aminol-butanediamide
20

Part A:

To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a
25 mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced pressure at 40°C and the residue dissolved in ethyl acetate
30 (approx. 1L). The solution was washed sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced
35 pressure. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was

recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp 150-151°C and $M+Li^+$ = 340.

5

Part B:

To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and MH^+ 298.

20

Part C:

A solution of N-benzyloxycarbonyl 3(S)-amino-1,2(S)-epoxy-4-phenylbutane (1.00g, 3.36 mmol) and isobutylamine (4.90g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into 100 mL of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 1.18g, 95% of N=[3(S)-phenylmethylcarbamoyl]amino-2(R)-hydroxy-4-phenylbutyl]N-[(2-methylpropyl)amine mp 108.0-109.5°C, MH^+ m/z = 371.

Part D:

A solution of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(2-methylpropyl)]amine in 10 ml of tetrahydrofuran was treated with tert-butylisocyanate (267 mg, 2.70 mmol) at room temperature for 5 minutes. The solvent was removed

in vacuo and replaced with ethyl acetate. The ethyl acetate solution was washed with 5% citric acid, water, and brine, dried over anhydrous MgSO_4 , filtered and concentrated in vacuo to give 1.19g 97% of [2(R), 3(S)]-N-
5 [[3-(phenylmethylcarbamoyl)-amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)]amino-2-(1,1-dimethylamino)carbonyl]butane, MH^+ m/z - 470.

Part E:

10 A solution of (1.00g, 2.21 mmol) [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)]amino-1-(1,1-dimethylethylamino)carbonyl]butane in 20 mL of methanol was hydrogenated over 10% palladium-on-carbon for 4 hours
15 to give [2(R), 3(S)]-N-[[3-amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)amino-1-(1,1-dimethylethylamino)carbonyl]butane 720 mg, 97%.

Part F:

20 A solution of N-Cbz-L-asparagine (602mg, 2.26 mmol) and n-hydroxybenzotriazole (493 mg, 3.22 mmol) in 2mL of dimethylformamide was cooled to 0°C and treated with EDC (473 mg, 2.47 mmol). The solution was allowed to stir at 0°C for 20 minutes and then treated with [2(R), 3(S)]-N-
25 [[3-amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)]amino-1-(1,1-dimethylethylamino)carbonyl]butane (720 mg, 2.15 mmol) in 1 mL of dimethylformamide. The solution was allowed to warm to room temperature and held at this temperature for 7 hours. The reaction mixture was then
30 poured into 100 mL of 60% saturated aqueous sodium bicarbonate whereupon a white precipitate formed that was isolated by filtration. The filter cake was washed with water, 5% aqueous citric acid, water and then dried in vacuo to give 1.04g, 83% of [1S-[1R*(R*), 2S*]]-N¹[3-
35 [[[(1,1-dimethylethyl)amino]-carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide, mp. 164.0-166.5°C, MH^+ m/z = 584.

Part G.

A solution of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-
5 [(phenylmethylcarbamoyl)-amino]-butanediamide (1.00g, 1.72 mmol) in 10 mL of methanol was hydrogenated over 10% palladium-on-carbon for 4 hours to give [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]-carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-amino]-butanediamide, 784mg, 99%.

Part H:

A mixture of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-amino]-butanediamide, (748 mg, 1.70 mmol), 2-quinoline carboxylic acid N-hydroxysuccinimide ester (459 mg, 1.70 mmol), N-methylmorpholine (343 mg, 3.40 mmol) in 5 mL of
20 dichloromethane was stirred at room temperature for 15 minutes. The solvent was removed in vacuo and replaced with ethyl acetate and the solution washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate, brine, dried over anhydrous MgSO₄, filtered and concentrated in
25 vacuo. The crude product was recrystallized from acetone/hexane to give 790 mg, 77% of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-amino]-butanediamide, mp 107.0-109.8°C, MH⁺ = 605.

30

Example 2Alternative preparations of the compound from Example 1.

Part E: N-[3S-Amino-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea
35

Part A: β-2-[Bis(phenylmethyl)amino]benzenepropanol

Method 1:

Step 1: A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 mL) was heated to 97°C. Benzyl bromide (108.5 mL, 0.605 mol) was then slowly added (addition time - 25 min). The mixture was stirred at 97°C for 30 minutes under a nitrogen atmosphere. The solution was cooled to room temperature and extracted with toluene (2 x 250 mL). The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and concentrated to an oil. The identity of the product was confirmed as follows. Analytical TLC (10% ethyl acetate/hexane, silica gel) showed major component at R_f value = 0.32 to be the desired tribenzylated compound, N,N-bis(phenylmethyl)-phenylalanine phenylmethyl ester. This compound can be purified by column chromatograph (silica gel, 15% ethyl acetate/hexanes). Usually the product is pure enough to be used directly in the next step without purification. ¹H NMR spectrum was in agreement with published literature EIMS: m/z 434 (M-1).

Step 2: The benzylated phenylalanine phenylmethyl ester (0.302 mol) from the previous reaction was dissolved in toluene (750 mL) and cooled to -55°C. A 1.5 M solution of DIABL in toluene (443.9 mL, 0.666 mol) was added at a rate to maintain the temperature between -55 and -50°C (addition time - 1 hr). The mixture was stirred for 20 minutes under a nitrogen atmosphere and then quenched at -55°C by the slow addition of methanol (37 mL). The cold solution was then poured into cold (5°C) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) was filtered off and washed with toluene. The solid material was suspended in a mixture of toluene (400 mL) and water (100 mL). The mixture was cooled to 5°C and treated with 2.5 N NaOH (186 mL) and then stirred at room

temperature until solid dissolved. The toluene layer was separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 mL (89 g). Ethyl acetate (25 mL) and hexane (25 mL) were added to the residue upon which the desired alcohol product began to crystallize. After 30 min, an additional 50 mL hexane were added to promote further crystallization. The solid was filtered off and washed with 50 mL hexane to give 34.9 g of first crop product. A second crop of product (5.6 g) was isolated by refiltering the mother liquor. The two crops were combined and recrystallized from ethyl acetate (20 mL) and hexane (30 mL) to give 50 g of β S-2-[Bis(phenylmethyl)amino]benzenepropanol, 40% yield from L-phenylalanine. An additional 7 g (7%) of product can be obtained from Recrystallization of the concentrated mother liquor. TLC of product R_f = 0.23 (10% ethyl acetate/hexane, silica gel); $[\alpha]_D^{25}$ = 42.4 (c 1.45, CH_2Cl_2); DSC 77.67°C; Anal. Calcd. for $\text{C}_{23}\text{H}_{25}\text{ON}$: C, 83.34; H, 7.60; N, 4.23. Found: C, 83.43; H, 7.59; N, 4.22. HPLC on chiral stationary phase: Cyclobond I SP column (250 x 4.6 mm I.D.), mobile phase: methanol/triethyl ammonium acetate buffer pH 4.2 (58:42, v/v), flow-rate of 0.5 ml/min, detection with detector at 230nm and a temperature of 0°C. Retention time: 11.25 min., retention time of the desired product enantiomer: 12.5 min.

Method 2:

L-phenylalaninol (176.6 g, 1.168 mol) was added to a stirred solution of potassium carbonate (484.6 g, 3.506 mol) in 710 mL of water. The mixture was heated to 65°C under a nitrogen atmosphere. A solution of benzyl bromide (400 g, 2.339 mol) in 3A ethanol (305 mL) was added at a rate that maintained the temperature between 60-68°C. The biphasic solution was stirred at 65°C for 55 min and then allowed to cool to 10°C with vigorous stirring. The oily product solidified into small granules. The product was

diluted with 2.0 L of tap water and stirred for 5 minutes to dissolve the inorganic by products. The product was isolated by filtration under reduced pressure and washed with water until the pH is 7. The crude product obtained
5 was air dried overnight to give a semi-dry solid (407 g) which was recrystallized from 1.1 L of ethyl acetate/heptane (1:10 by volume). The product was isolated by filtration (at -8°C), washed with 1.6 L of cold (-10°C) ethyl acetate/heptane (1:10 by volume) and
10 air dried to give 339 g (88% yield) of β S-2-[Bis(phenylmethyl)amino]benzene-propanol, mp 71.5-73.0°C. More product can be obtained from the mother liquor if necessary. The other analytical characterization was identical to compound prepared as described in Part A,
15 Method 2.

Part B: aS-

[Bis(phenylmethyl)amino]benzenepropanaldehyde

20 Method 1:

β -2-[Bis(phenylmethyl)amino]benzene-propanol (200 g, 0.604 mol) was dissolved in triethylamine (300 mL, 2.15 mol). The mixture was cooled to 12°C and a solution of sulfur trioxide/pyridine complex (380 g, 2.39 mol) in DMSO
25 (1.6 L) was added at a rate to maintain the temperature between 8-17°C (addition time - 1.0 h). The solution was stirred at ambient temperature under a nitrogen atmosphere for 1.5 hour at which time the reaction was complete by TLC analysis (33% ethyl acetate/hexane, silica gel). The
30 reaction mixture was cooled with ice water and quenched with 1.6 L of cold water (10-15°C) over 45 minutes. The resultant solution was extracted with ethylacetate (2.0 L), washed with 5% citric acid (2.0 L), and brine (2.2 L), dried over MgSO_4 (280 g) and filtered. The solvent was
35 removed on a rotary evaporator at 35-40°C and then dried under vacuum to give 198.8 g of aS-[Bis-(phenylmethyl)amino]-benzenepropanaldehyde as a pale yellow oil (99.9%). The crude product obtained was pure

enough to be used directly in the next step without purification. The analytical data of the compound were consistent with the published literature. $[\alpha]_D^{25} = -92.9^\circ$ (c 1.87, CH_2Cl_2); HRMS calcd for $(M+1)$ $\text{C}_{23}\text{H}_{24}\text{NO}$ 330.450, found: 330.1836. Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{NO}$: C, 83.86; H, 7.04; N, 4.25. Found: C, 83.64; H, 7.42; N, 4.19. HPLC on chiral stationary phase: (S<S) Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector at 210nm. Retention time of the desired S-isomer: 8.75 min., retention time of the R-enantiomer 10.62 min.

Method 2:

15 A solution of oxalyl chloride (8.4 ml, 0.096 mol) in dichloromethane (240 ml) was cooled to -74°C . A solution of DMSO (12.0 ml, 0.155 mol) in dichloromethane (50 ml) was then slowly added at a rate to maintain the temperature at -74°C (addition time about 1.25 hr). The mixture was stirred for 5 min. followed by addition of a solution of RS-2-[bis(phenylmethyl)amino]benzene-propanol (0.74 mol) in 100 ml of dichloromethane (addition time -20 min., temp. -75°C to -68°C). The solution was stirred at -78°C for 35 minutes under nitrogen atmosphere.

25 Triethylamine (41.2 ml, 0.295 mol) was then added over 10 min. (temp. -78°C to -68°C) upon which the ammonium salt precipitated. The cold mixture was stirred for 30 min. and then water (225 ml) was added. The dichloromethane layer was separated from the aqueous phase and washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The residue was diluted with ethyl acetate and hexane and then filtered to further remove the ammonium salt. The filtrate was concentrated to give aS-[bis(phenylmethyl)amino]benzenepropanaldehyde. The aldehyde was carried on to the next step without purification.

Method 3:

To a mixture of 1.0 g (3.0 mmol) of β S-2-[bis(phenylmethyl)amino]benzenepropanol 0.531 g (4.53 mmol) of N-methyl morpholine, 2.27 g of molecular sieves (4A) and 9.1 mL of acetonitrile was added 53 mg (0.15 mmol) of tetrapropylammonium purethenate (TPAP). The mixture was stirred for 40 minutes at room temperature and concentrated under reduced pressure. The residue was suspended in 15 mL of ethyl acetate, filtered through a pad of silica gel. The filtrate was concentrated under reduced pressure to give a product containing approximately 50% of α S-2-[bis(phenylmethyl)amino]benzene propanaldehyde as a pale yellow oil.

Method 4:

To a solution of 1.0 g (3.02 mmol) of β S-2-[bis(phenylmethyl)amino]benzenepropanol in 9.0 mL of toluene was added 4.69 mg (0.03 mmol) of 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO), 0.32 g (3.11 mmol) of sodium bromide, 9.0 mL of ethyl acetate and 1.5 mL of water. The mixture was cooled to 0°C and an aqueous solution of 2.87 mL of 5% household bleach containing 0.735 g (8.75 mmol) of sodium bicarbonate and 8.53 mL of water was added slowly over 25 minutes. The mixture was stirred at 0°C for 60 minutes. Two more additions (1.44 mL each) of bleach was added followed by stirring for 10 minutes. The two phase mixture was allowed to separate. The aqueous layer was extracted twice with 20 mL of ethyl acetate. The combined organic layer was washed with 4.0 mL of a solution containing 25 mg of potassium iodide and water (4.0 mL), 20 mL of 10% aqueous sodium thiosulfate solution and then brine solution. The organic solution was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 1.34 g of crude oil containing a small amount of the desired product aldehyde, α S-[bis(phenylmethyl)amino]benzenepropanaldehyde.

Method 5:

Following the same procedures as described in Part B, Method 1 except 3.0 equivalents of sulfur trioxide pyridine complex was used and aS-
5 [bis(phenylmethyl)amino]benzenepropanaldehyde was isolated in comparable yields.

Part C: N,NaS-Tris(phenylmethyl)-2S-oxiranemethanamine

10

Method 1:

A solution of aS-[Bis(phenylmethyl)amino]benzene-propanaldehyde (191.7 g, 0.58 mol) and chloriodomethane (56.4 mL, 0.77 mol) in tetrahydrofuran (1.8 L) was cooled
15 to -30 to -35°C (colder temperature such as -70°C also worked well but warmer temperatures are more readily achieved in large scale operations) in a stainless steel reactor under a nitrogen atmosphere. A solution of n-butylolithium in hexane (1.6 M, 365 mL, 0.58 mol) was then
20 added at a rate that maintained the temperature below -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. More additions of reagents were carried out in the following manner: (1) additional chloriodomethane (17 mL) was added, followed by n-
25 butylolithium (110 mL) at < -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. (2) Additional chloriodomethane (8.5 mL, 0.11 mol) was added, followed by n-butylolithium (55 mL, 0.088 mol) at < -25°C. After addition the mixture was
30 stirred at -30 to -35°C for 10 minutes. This was repeated 5 times. (3) Additional chloriodomethane (8.5 mL, 0.11 mol) was added, followed by n-butylolithium (37 mL, 0.059 mol) at < -25°C. After addition the mixture was stirred at
35 -30 to -35°C for 10 minutes. This was repeated once. The external cooling was stopped and the mixture warmed to ambient temp. over 4 to 16 hours when TLC (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was completed. The reaction mixture was cooled to 10°C and

quenched with 1452 g of 16% ammonium chloride solution (prepared by dissolving 232 g of ammonium chloride in 1220 mL of water), keeping the temperature below 23°C. The mixture was stirred for 10 minutes and the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 mL). The ethyl acetate layer was combined with tetrahydrofuran layer. The combined solution was dried over magnesium sulfate (220 g), filtered and concentrated on a rotary evaporator at 65°C. The brown oil residue was dried at 70°C in vacuo (0.8 bar) for 1 h to give 222.8 g of crude material. (The crude product weight was 100%. Due to the relative instability of the product on silica gel, the crude product is usually used directly in the next step without purification). The diastereomeric ratio of the crude mixture was determined by proton NMR: (2S)/(2R): 86.14. The minor and major epoxide diastereomers were characterized in this mixture by tlc analysis (silica gel, 10% ethyl acetate/hexane), R_f = 0.29 & 0.32, respectively. An analytical sample of each of the diastereomers was obtained by purification and characterized as follows: N,N,aS-Tris(phenylmethyl)-2S-oxiranemethanamine, HRMS calcd for $C_{22}H_{26}NO$ (M+1) 344.477, found 344.2003; and N,N,aS-Tris(phenylmethyl)-2R-oxiranemethanamine, HPLC on chiral stationary phase: Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 mL/min, detection with UV detector at 210 nm. Retention time of (8): 9.38 min., retention time of enantiomer of (4): 13.75 min.

Method 2:

A solution of the crude aldehyde 0.074 mol and chloriodomethane (7.0 mL, 0.096 mol) in tetrahydrofuran (285 mL) was cooled to -78°C, under a nitrogen atmosphere. A 1.6 M solution of n-butyllithium in hexane (25 mL, 0.040 mol) was then added at a rate to maintain the temperature at -75°C (addition time - 15 min.). After the first addition, additional chloriodomethane (1.6 mL, 0.022 mol)

was added again, followed by n-butyllithium (23 ml, 0.037 mol), keeping the temperature at -75°C. The mixture was stirred for 15 min. Each of the reagents, chloriodomethane (0.70 ml, 0.010 mol) and n-butyllithium (5 ml, 0.008 mol) were added 4 more times over 45 min. at -75°C. The cooling bath was then removed and the solution warmed to 22°C over 1.5 hr. The mixture was poured into 300 ml of saturated aq. ammonium chloride solution. The tetrahydrofuran layer was separated. The aqueous phase was extracted with ethyl acetate (1 x 300 ml). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to give a brown oil (27.4 g). The product could be used in the next step without purification. The desired diastereomer can be purified by recrystallization at a subsequent step. The product could also be purified by chromatography.

Method 3:

A solution of aS-[Bis(phenylmethyl)amino]benzene-propanaldehyde (178.84 g, 0.54 mol) and bromochloromethane (46 mL, 0.71 mol) in tetrahydrofuran (1.8 L) was cooled to -30 to -35°C (colder temperature such as -70°C also worked well but warmer temperatures are more readily achieved in large scale operations) in a stainless steel reactor under a nitrogen atmosphere. A solution of n-butyllithium in hexane (1.6 M, 340 mL, 0.54 mol) was then added at a rate that maintained the temperature below -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. More additions of reagents were carried out in the following manner: (1) additional bromochloromethane (14 mL) was added, followed by n-butyllithium (102 mL) at <-25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. (2) Additional bromochloromethane (7 mL, 0.11 mol) was added, followed by n-butyllithium (51 mL, 0.082 mol) at <-25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated 5 times. (3) Additional bromochloromethane (7 mL, 0.11 mol) was added, followed by

n-butyllithium (51 mL, 0.082 mol) at $<-25^{\circ}\text{C}$. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. The external cooling was stopped and the mixture warmed to ambient temp. over 4
5 to 16 hours when TLC (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was completed. The reaction mixture was cooled to 10°C and quenched with 1452 g of 16% ammonium chloride solution (prepared by dissolving 232 g of ammonium chloride in 1220 mL of
10 water), keeping the temperature below 23°C . The mixture was stirred for 10 minutes and the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 ml). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined
15 solution was dried over magnesium sulfate (220 g), filtered and concentrated on a rotary evaporator at 65°C . The brown oil residue was dried at 70°C in vacuo (0.8 bar) for 1 h to give 222.8 g of crude material.

20 Method 4:

Following the same procedures as described in Part C, Method 3 except the reaction temperatures were at -20°C . The resulting N,N,aS-tris(phenylmethyl)-2S-oxiranemethanamine was a diastereomeric mixture of lesser
25 purity than that of Method 3.

Method 5:

Following the same procedure as described in Part C, Method 3 except the reaction temperatures were at -70 to
30 -78°C . The resulting N,N,aS-tris(phenylmethyl)-2S-oxiranemethanamine was a diastereomeric mixture, which was used directly in the subsequent steps without purification.

35 Method 6:

Following the same procedures as described in Part C, Method 3 except a continuous addition of bromochloromethane and n-butyllithium was used at -30 to

-35°C. After the reaction and work up procedures as described in Method 3, the desired N,N,aS-tris(phenylmethyl)-2S-oxiranemethanamine was isolated in comparable yields and purities.

5

Method 7:

Following the same procedures as described in Part C, Method 2 except dibromomethane was used instead of chloriodomethane. After the reaction and work up
10 procedures as described in Method 2, the desired N,N,aS-tris(phenylmethyl)-2S-oxirane-methanamine was isolated.

Part D: 3S-[N,N-Bis(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2R-ol

15 To a solution of crude N,N,aS-tris(phenylmethyl)-2S-oxiranemethanamine (388.5 g, 1.13mol) from Part C in isopropanol (2.7 L) (or ethyl acetate) was added isobutylamine (1.7 kgm, 23.1 mol) over 2 min. The temperature increased from 25°C to 30°C. The solution was
20 heated to 82°C and stirred at this temperature for 1.5 h. The warm solution was concentrated under reduced pressure at 65°C. The brown oil residue was transferred to a 3-L flask and dried in vacuo (0.8 mm Hg) for 16 h to give 450 g of 3S-[N,N-bis(phenylmethyl)amino]-1-(2-
25 methylpropyl)amino-4-phenylbutan-2R-ol as a crude oil. The product was used directly in the next step without purification. An analytical sample of the desired major diastereomeric product was obtained by purifying a small sample of crude product by silica gel chromatography (40%
30 ethyl acetate/hexane). Tlc analysis: silica gel, 40% ethyl acetate/hexane; R_f = 0.28; HPCL analysis: ultrasphere ODS column, 25% triethylamino-/phosphate buffer pH 3/acetonitrile, flow rate 1 mL/min, UV detector; retention time 7.49 min.; HRMS calcd for C₂₈H₃₇N₂O (= 1)
35 417.616, found 417.2887. An analytical sample of the minor diastereomeric product, 3S-[N,N-bis(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2S-ol was also obtained by purifying a small

sample of crude product by silica gel chromatography (40% ethyl acetate/hexane).

Part E: N-[3S-[N,N-Bis(phenylmethyl)amino]-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea

A solution of the crude 3S-[N,N-Bis(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2R-ol (446.0 g, 1.1 mol) from Example 4 in tetrahydrofuran (6 L) (or ethylacetate) was cooled to 8°C. t-Butyl isocyanate (109.5 g, 1.1 mol) was then added to the solution of the amine from an addition funnel at a rate that maintained the temperature between 10-12°C (addition time was about 10 min). The external cooling was stopped and the reaction was warmed to 18°C after 30 min. The solution was transferred directly from the reactor to a rotary evaporator flask (10 L) through a teflon tube using vacuum and then concentrated. The flask was heated in a 50°C water bath during the 2 h required for the distillation of the solvent. The brown residue was dissolved in ethyl acetate (3L), washed with 5% aq citric acid solution (1 x 1.2 L), water (2 x 500 mL), brine (1 x 400 mL), dried over magnesium sulfate (200 g) and filtered. The volume of product solution was reduced to 671 mL over 2 h on a rotary evaporator at 50°C. The concentrate was stirred and diluted with 1.6 L of hexane. The mixture was cooled to 12°C and stirred for 15 hours. The product crystals were isolated by filtration, washed with 10% ethyl acetate/hexane (1 x 500 mL), hexane (1 x 200 mL) and dried in vacuo (2 mm) at 50°C for 1 hour to give 248 g of N-[3S-[N,N-bis-(phenylmethyl)amino]-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)-urea. The mother liquor and washes were combined and concentrated on a rotary evaporator to give 270 g of a brown oil. This material was dissolved in ethyl acetate (140 mL) at 50°C and diluted with hexane (280 mL) and seeded with crystals of the first crop product (20 mg). The mixture was cooled in an ice bath and stirred for 1 h. The solid was isolated by

filtration, washed with 10% ethyl acetate/hexane (1 x 200 mL) and dried in vacuo (2 mm) at 50°C for 1 h to give 55.7 g of product as the second crop (49% overall yield. Mp 126°C; $[\alpha]_{D25} = -59.0^\circ\text{C}$ ($c = 1.0$, CH_2Cl_2), TLC: Rf 0.31
 5 (silica gel, 25% ethyl acetate/hexane).

Part F: N-[2S-Amino-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea

N-[3S-[N,N-Bis(phenylmethyl)amino]-2E-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea
 10 (125.77 g, 0.244 mol) was dissolved in ethanol (1.5 L) (or methanol) and 20% palladium hydroxide on carbon (18.87 g) (or 4% palladium on carbon) was added to the solution under nitrogen. The mixture was stirred at ambient
 15 temperature under a hydrogen atmosphere at 60 psi for approximately 8 h. The catalyst was removed by filtration and the filtrate was concentrated to give 85 g of N-[3S-Amino-2R-hydroxy-4-phenylbutyl]-N'-(1,1-dimethylethyl)-N-(2-methylpropyl)urea as a colorless oil.

20 Further elaboration on the methods of Example 2 are contained in US patent application Serial No. 08/156,498, filed November 23, 1993, incorporated herein by reference in its entirety.

25 Example 3

Preparation And Characterization of Emulsifiable Concentrate

30 N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide (0.5 g, 5% w/w) was dissolved in absolute ethanol (3.5 g, 35% w/w) by soaking
 35 for fifteen minutes followed by gentle mixing until a clear solution was obtained. To this solution was added Tagat TO (3.5 g, 35% w/w) and the mixture gently mixed to a clear solution. Neobee M5 oil (2.5 g, 25% w/w) was

added to the mixture and gently mixed resulting in a clear slightly viscous solution of the emulsifiable concentrate. The corresponding 2.5% w/w emulsifiable concentrate of the pharmaceutical was also prepared by the same procedure with essentially the same ratio of the other ingredients. The corresponding 15% w/w emulsifiable concentrate of the pharmaceutical was also prepared by the same procedure in 35% w/w ethanol, 40% w/w Tagat TO and 10% w/w Neobee oil. The ethanol concentration of about a 2% w/w emulsifiable concentrate of the pharmaceutical may be reduced to 2% w/w when the Tagat TO concentration is increased to 46% w/w, Neobee oil concentration to 46% w/w and propylene glycol added to a concentration of 4% w/w.

15

Example 4

The emulsifiable concentrate of Example 3 was mixed with water (distilled) at pH 5 of 0.1 N hydrochloric acid (pH 1) to form a turbid solution. At an emulsifiable concentrate:water ratio of 1:50, 1:100 and 1:200, the majority of emulsion particles were measured using dynamic light scattering techniques by laser optics particle sizing (Brookhaven Labs digital collator and Lexal argon ion laser) to be within the range 20 to 25 nm in diameter. The measurement was taken after further diluting an aliquot of the 1:50 ratio mixture to 1:200. The emulsifiable concentrate/water emulsion was stable for at least four hours at 5°C. At an emulsifiable concentrate:water ratio of 1:8, the mixture formed a gel in about ten minutes. Promptly further diluting the 1:8 mixture with 0.1 N hydrochloric acid formed a microemulsion which was stable for at least one hour at ambient temperature. An emulsion of the corresponding 2.5% w/w emulsifiable concentrate of the pharmaceutical from Example 3 was also prepared and found to form microemulsions upon dilution in water.

Tables 1-3 list the typical particle size distributions (PSD) obtained when the emulsifiable concentrate of Example 3 was mixed as described above in a ration of 1:50 with water (pH 5), 0.1 N hydroxylchlorid acid (pH 1) and the soluble fraction of a partially gelled emulsion in water after standing at 5°C for one week. The soluble fraction was obtained by centrifuging the mixture in a microcentrifuge for two minutes to produce a clarified solution. The soluble fraction Dilution in water produced a small particle with a peak diameter of 22 nm and a mean diameter of 52 nm which includes a weak contribution from an ill-defined larger diameter mode. Dilution in 0.1 N HCl produced a bimodal particle size distribution with peak diameters of 25 nm and 86 nm and a mean diameter of 61 nm.

Table 1

PSD Of Emulsifiable Concentrate In Water 1:50

d/nm ¹	G(d) ²	C(d) ³	d/nm	G(d)	C(d)	d/nm	G(d)	C(d)
3	0	0	21	100	58	110	0	95
4	0	0	25	86	83	128	0	95
5	0	0	29	33	92	149	0	95
6	0	0	33	9	95	173	0	95
7	0	0	39	0	95	201	0	95
9	0	0	45	0	95	234	0	95
10	0	0	52	0	95	272	7	97
12	0	0	61	0	95	316	6	98
13	0	0	70	0	95	367	6	100
16	22	6	82	0	95	dust	0	100
18	81	29	95	0	95			

¹d/nm = diameter in nanometers of standard²G(d) = differential particle size distribution³C(d) = cumulative particle size distribution

Table 2

PSD Of Emulsifiable Concentrate In 0.1N HCl 1:50

d/nm ¹	G(d) ²	C(d) ³	d/nm	G(d)	C(d)	d/nm	G(d)	C(d)
-------------------	-------------------	-------------------	------	------	------	------	------	------

3	0	0	22	41	33	114	0	100
4	0	0	25	15	83	133	0	100
5	0	0	29	0	92	155	0	100
6	0	0	34	0	95	180	0	100
7	0	0	40	0	95	209	0	100
9	0	0	46	16	95	244	0	100
10	0	0	53	62	95	284	0	100
12	0	0	62	96	95	338	0	100
14	23	4	72	100	95	384	0	100
16	51	14	84	56	95	dust	0	100
19	66	26	98	21	95			

¹d/nm = diameter in nanometers of standard

²G(d) = differential particle size distribution

³C(d) = cumulative particle size distribution

5

Table 3

PSD Of Soluble Fraction Of Partially Gelled
Emulsifiable Concentrate (Example 3) In Water 1:50

d/nm ¹	G(d) ²	C(d) ³	d/nm	G(d)	C(d)	d/nm	G(d)	C(d)
3	0	0	21	53	18	107	0	93
4	0	0	24	88	42	124	0	93
5	0	0	28	100	69	144	0	93
6	0	0	32	62	86	167	2	94
7	0	0	38	26	93	194	3	95
9	0	0	44	0	93	225	6	96
10	0	0	51	0	93	261	7	98
11	0	0	59	0	93	303	5	99
13	0	0	68	0	93	352	2	100
15	0	0	79	0	93	dust	0	100
18	12	3	92	0	93			

¹d/nm = diameter in nanometers of standard

²G(d) = differential particle size distribution

10 ³C(d) = cumulative particle size distribution

Example 5

N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide had a
5 bioavailability of <1% using normal formulation methods apparently due to poor water and oil solubility. When it was administered as a suspension in tween 80, methylcellulose and water to rats, its bioavailability was about 1%. When crystals of the pharmaceutical were
10 micronized in a Trost Micronizer Apparatus and administered (10 and 100 mg/kg) to dogs in a capsule, no detectable plasma concentration was observed (see Example 7).

15

Example 6

Preparation And Characterization Of Elixir

N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide (18.75 g) was
20 dissolved in 96% ethanol (117.5 ml) by soaking for ten minutes followed by mixing until a clear solution was obtained. To this solution was added peppermint flavor (15 ml) and the mixture gently mixed to a clear solution. Water (37.5 ml) was added to the mixture and gently mixed
25 resulting in a clear solution of the elixir. The elixir was stored at room temperature protected from light and was not generally used after 21 days.
30

Example 7

Oral administration to Dogs and Rats

35

Dogs: N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-

(phenylmethyl)propyl]-2(S)-[N³-(2-quinolinylcarbonyl)amino]butanediamide was administered in a nonrandomized crossover design to four female beagle dogs in a series of formulations: (1) elixir (10 mg/kg) (Example 6); (2) a PVP coprecipitate (20 mg/kg/) {prepared as follows: polyvinylpyrrolidone (PVP) and the pharmaceutical (ratio of 2.2 w/w) were dissolved in ethanol and then the solvent was removed in vacuo; the resulting solids were ground to a fine powder and dosed in capsules}; (3) micronized crystals of the pharmaceutical (10 and 100 mg/kg) (Example 5); (4) SEDDS I (20 mg/kg/ {emulsifiable concentrate comprising the pharmaceutical (5% w/w), Myglyol (35% w/w), ethanol (15% w/w) and labrafil CS2125 (45% w/w), prepared according to the method of Example 3 was mixed in a ratio of 1:10 with water}); and (5) SEDDS II (20 mg/kg) {emulsifiable concentrate of Example 3 was mixed in a ratio of 1:10 with water}. The dogs were given each formulation in the fasted state. The dogs were also given the elixir and SEDDS I formulations with a high fatty meal. After each dose, blood samples were taken from the dogs at 0.25, 0.5, 1, 1.5, 2, 3, 5 and 7 hours. Plasma was obtained by centrifugation and the samples were frozen and stored for analysis.

The pharmaceutical was obtained by solid phase extraction from the plasma and the extracts were analyzed by HPLC. The plasma concentrations of the pharmaceutical were determined and for each dosage form the area under the plasma concentration time curve (AUC), peak plasma concentration (C_{max}) and time to reach the peak plasma concentration (T_{max}) were calculated. The data is summarized in Table 4.

There were no detectable concentrations of the pharmaceutical after administration of the micronized form of the pharmaceutical at 10 and 100 mg/kg doses in dogs. The data demonstrate that the pharmaceutical was systematically available after administration of the PVP

coprecipitate but the concentrations were very low (under 100 ng/ml). Administration of the alcohol elixir or either of the two SEDDS formulations resulted in higher peak plasma concentrations and AUCs than the coprecipitate. In addition, administering the elixir with food reduced the plasma concentrations of the pharmaceutical as compared to giving the elixir fasted. For the SEDDS vehicle, however, food enhanced the bioavailability of the pharmaceutical.

Table 4

Mean Pharmacokinetic Parameters after Oral
Administration
of Various Dosage Forms to Female Beagle Dogs

Dosage Form	Dose (mg/kg)	AUC (ng/mL)hr	C _{max} (ng/mL)	t _{max} (hr)
Elixir				
Fasted	10.0	413.±132	648.±249	0.813±0.400
Fed	10.0	148.±102	222.±106	0.375±0.072
Emulsion (SEDDS I)				
Fasted	20.0	162.±93	97.5±37.6	0.563±0.313
Fed	20.0	319.±106	213.±68	0.750±0.421
PVP Coprecipitate				
Fasted	20.0	71.0±20.1	59.4±10.7	1.38±0.55
Emulsion (SEDDS II)				
Fasted	20.0	514.±111	290.±52	1.44±0.41

Rats: N¹-[3-[N²-[(1,1-dimethylethyl)amino]carbonyl]-N²-(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N³-(2-quinolinylcarbonyl)amino]butanediamide was orally administered in vehicles containing

5 polyethylene glycol 400, propylene glycol, ethanol and tween 80 (PPE-tween) or in the SEDDS II formulation. Three rats were administered with each dose vehicle. Plasma samples were obtained at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours after dose administration. Plasma

10 concentrations of the pharmaceutical were determined as previously described in the dog and the same pharmacokinetic parameters were determined. Results are given in Table 5. The data show that in this study the SEDDS II formulation gave the highest plasma

15 concentrations of the pharmaceutical as compared to the PPE-tween vehicle.

Table 5

20 Male Rat Pharmacokinetic Parameters of the Mean Plasma Concentrations after Oral Administration

	Dose	Dose	AUG ^a ±SEM ^b	Cmax ^c ±SEM ^b	Tmax ^d ±SEM ^b
	Vehicle	(mg/kg)	(µg/mL)hr	(µg/mL)	(hr)
25	SEDDS II	300	7.61±2.60	1.59±0.50	
	1.58±1.21				
	5% Tween	300	0.966±0.400	0.422±.189	0.25±0.0
	10% Tween	300	1.27±0.24	0.837±0.228	
	0.333±0.083				

30

Example 8

Single oral doses of N¹-[3-[N²-[(1,1-dimethylethyl)amino]carbonyl]-N²-(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N³-(2-quinolinylcarbonyl)amino]butanediamide (500 mg) were

35 administered to human subjects as: (1) elixir (Example 6) to subjects which fasted overnight for approximately ten

hours prior to each treatment (elixir fasting); (2) emulsifiable concentrate (Example 3) mixed as described above in a ratio of 1:10 in apple juice to subjects which fasted overnight for approximately ten hours prior to each treatment (SEDDS fasting); and (3) emulsifiable concentrate (Example 3) mixed as described above in a ratio of 1:10 in apple juice to subjects immediately following a high fat breakfast (SEDDS fed). Eighteen subjects (HIV positive non-symptomatic individuals) completed the three treatments in a randomized, balanced, crossover study. Figure 1 shows the plasma concentration-time curves of the pharmaceutical with elixir fasting and SEDDS fasting. Figure 2 shows the plasma concentration-time curves of the pharmaceutical with elixir fasting and SEDDS fed. Relative to elixir, the pharmaceutical bioavailability from SEDDS given under fasting state demonstrated no controlled release characteristics (Fig. 1). However, when SEDDS was given with food, not only was there excellent bioavailability (about 90% relative to elixir) but a highly desirable controlled release profile was obtained (Fig. 2). Mean plasma levels were almost 50 times the IC_{50} (10 ng/mL) at C_{max} and thereafter remained above IC_{50} throughout the eight-hour projected dosing intervals. Also, means concentrations were above IC_{90} (100 ng/mL) for almost five hours after the single dose (Figure 3). Simulated steady state plasma concentration-time curves (Figure 4) show that compared to elixir, plasma level with SEDDS fed remain above IC_{90} for a longer period (shaded horizontal bars).

30

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

35

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications
5 of the invention to adapt it to various usages and conditions.

What is claimed is:

1. An oral pharmaceutical composition comprising
 - a) a pharmaceutical which is substantially
5 water and oil insoluble;
 - b) an edible emulsifier;
 - c) an edible oil; and
 - d) an edible solubilizer.
- 10 2. The composition of Claim 1 wherein
 - a) said pharmaceutical is at a concentration
within the range of about 0.1 to about 17% (w/w);
 - b) said emulsifier is at a concentration within
the range of about 10 to about 55% (w/w);
 - 15 c) said oil is at a concentration within the
range of about 10 to about 50% (w/w); and
 - d) said solubilizer is at a concentration
within the range of about 2 to about 50% (w/w).
- 20 3. The composition of Claim 2 wherein
 - a) said pharmaceutical is at a concentration
within the range of about 2 to about 10% (w/w);
 - b) said emulsifier is at a concentration within
the range of about 10 to about 45% (w/w);
 - 25 c) said oil is at a concentration within the
range of about 10 to about 45% (w/w); and
 - d) said solubilizer is at a concentration
within the range of about 5 to about 40% (w/w).
- 30 4. The composition of Claim 3 wherein
 - a) said pharmaceutical is at a concentration
within the range of about 5 to about 10% (w/w);
 - b) said emulsifier is at a concentration within
the range of about 30 to about 45% (w/w);
 - 35 c) said oil is at a concentration within the
range of about 25 to about 45% (w/w); and
 - d) said solubilizer is at a concentration
within the range of about 10 to about 35% (w/w).

5. The composition of Claim 1 wherein

a) said pharmaceutical is N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-quinolinylcarbonyl)amino]butanediamide;

b) said emulsifier is selected from the group consisting of polyoxyethylene glycerol esters of fatty acids, ethylene glycol esters, propylene glycol esters, propylene glycol esters; glyceryl esters of fatty acids, sorbitan esters, polyglyceryl esters, fatty alcohol ethoxylates, ethoxylated propoxylated block copolymers, polyethylene glycol esters of fatty acids, cremophores, and glyceryl monocaprylate/caprate;

c) said oil is selected from the group consisting of Neobee oil, Myglyol derivatives, soy oil, almond oil, olive oil, peanut oil and medium chain triglycerides of about 8 to about 10 carbon atoms; and

d) ~~said solubilizer~~ is selected from the group consisting of ethanol, sweet peppermint flavor, orange oil flavor, cherry flavor, raspberry flavor, lemon oil flavor, oleic acid, linoleic acid, propylene glycol, butyric acid propionic acid, lauryl alcohol, limonene, myristyl alcohol and polyethylene glycol.

6. The composition of Claim 5 wherein

- a) said emulsifier is Tagat TO;
b) said oil is Neobee oil; and
c) said solubilizer is ethanol.

7. The composition of Claim 6 wherein

a) said N^1 -[3-[N^2 -[(1,1-dimethylethyl)amino]carbonyl]- N^2 -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N^3 -(2-

quinolinylcarbonyl)amino]butanediamide is at a concentration of about 5% (w/w);

b) said Tagat TO is at a concentration of about 35% (w/w);

5 c) said Neobee oil is at a concentration of about 25% (w/w); and

d) said ethanol is at a concentration of about 35% (w/w).

10 8. The composition of Claim 1 further comprising a second pharmaceutical which is water soluble, oil soluble, or substantially water and oil insoluble.

9. The composition of Claim 8 wherein said second
15 pharmaceutical is an enzyme inhibitor.

10. The composition of Claim 1 further comprising an aqueous solution having a pH within the range of about 3 to about 8.5.

20

11. The composition of Claim 10 wherein the aqueous solution has a pH within the range of about 5 to about 7.5.

25 12. The composition of Claim 10 wherein the oil:water ratio is within the range of about 1:5 to about 1:1000.

13. The composition of Claim 12 wherein the
30 oil:water ratio is within the range of about 1:50 to about 1:200.

14. Process for preparing a pharmaceutical composition wherein the composition of Claim 1 is combined
35 with an aqueous solution having a pH within the range of about 1 to about 8 at an oil:water ratio within the range of about 1:5 to about 1:1000.

15. The process of Claim 14 wherein the aqueous solution has a pH within the range of about 5 to about 7.5 and the oil:water ratio is within the range of about 1:50 to about 1:200.

16. An oral pharmaceutical composition consisting essentially of a pharmaceutical, which is substantially water and oil insoluble, and an aqueous solution of solublizer.


17. The composition of Claim 16 wherein the pharmaceutical is at a concentration within the range of about 0.1% (w/w) to about 17% (w/w) and the solublizer is at a concentration within the range of about 40% (w/w) to about 90% (w/w).

18. The composition of Claim 17 wherein the pharmaceutical is at a concentration within the range of about 2% (w/w) to about 10% (w/w) and the solublizer is at a concentration within the range of about 50% (w/w) to about 80% (w/w).

19. The composition of Claim 18 wherein the pharmaceutical is at a concentration within the range of about 2% (w/w) to about 10% (w/w) and the solublizer is at a concentration within the range of about 60% (w/w) to about 80% (w/w).


20. The composition of Claim 16 wherein the solublizer is ethanol.

1/4




2/4

Figure 2




3/4

Figure 3



4/4

Figure 4



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/08227

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/107 A61K47/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A, 95 07696 (ABBOTT LABORATORIES) 23 March 1995 see page 3, line 1 - line 4 see page 23; example 10 see page 28 - page 29; examples 25-28 see page 36; example 42 see page 37; example 44 ---	1-6, 16-19
X	DE, A, 32 25 706 (A. NATTERMANN & CIE GMBH) 12 January 1984 see page 9, line 11 - line 12 see page 9; example 1 ---	1-4, 10-14
X	EP, A, 0 156 507 (ORTHO PHARMACEUTICAL CORPORATION) 2 October 1985 see page 10, line 10 - line 15 ---	16-20
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search 13 November 1995	Date of mailing of the international search report 21.11.1995
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer Benz, K

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/US 95/08227

C.(Continuation) D. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 418 553 (BAUER ET AL.) 27 March 1991 see column 6, line 54 - column 7, line 13 see claims 1-5 ---	16-19
X	EP,A,0 522 937 (RHONE-POULENC RORER SA) 13 January 1993 see the whole document ---	1-19
X	EP,A,0 517 412 (MERCK SHARP & DOHME LTD.) 9 December 1992 see the whole document see page 2, line 22 - line 23 see page 2, line 39 - line 40 -----	1,2,10, 11

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No.

PCT/US 95/08227

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9507696	23-03-95	AU-B- 7717694	03-04-95
DE-A-3225706	12-01-84	EP-A, B 0100448	15-02-84
		JP-A- 59022651	04-02-84
		US-A- 4567161	28-01-86
EP-A-156507	02-10-85	US-A- 4912124	27-03-90
		CA-A- 1241603	06-09-88
EP-A-418553	27-03-91	DE-A- 3927882	28-02-91
		US-A- 5258185	02-11-93
EP-A-522937	13-01-93	FR-A- 2678833	15-01-93
		AU-A- 2278792	11-02-93
		CZ-A- 9400032	15-02-95
		EP-A- 0522936	13-01-93
		EP-A- 0593601	27-04-94
		EP-A- 0593656	27-04-94
		WO-A- 9300928	21-01-93
		WO-A- 9300929	21-01-93
		HU-A- 65960	29-08-94
		JP-T- 6507913	08-09-94
		JP-T- 6507914	08-09-94
		NO-A- 934609	14-12-93
		NO-A- 934610	14-12-93
		US-A- 5403858	04-04-95
EP-A-517412	09-12-92	AU-A- 1766592	08-01-93
		WO-A- 9221348	10-12-92